ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
07/10/2025
Back to search
Official data from USPTO
FISGENIQ
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
18
Latest update
07/11/2025
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
12/03/2021
Registration date
04/11/2023
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/11/2023
Last transaction
07/11/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
25
Owner location
GLATTPARK-OPFIKON, CH
Examiner
PORTARO, ALEXANDRA
Law office
N80
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
TAKEDA PHARMACEUTICALS INTERNATIONAL AG
TiGenix, S.A.U.
Representatives
Karl M. Zielaznicki, Esq. TROUTMAN PEPPER HAMILTON SANDERS LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for use in gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of fistulasfistulas in Crohn's disease patientscomplex perianal fistulas and complex perianal fistulas in Crohn's diseases patients; pharmaceutical and diagnostic preparations for medical purposes for the treatment of fistulas in Crohn's disease patientscomplex perianal fistulas and complex perianal fistulas in Crohn's diseases patients; cellular functioning activating agentsbiological or bacteriological preparations for medical purposes for the treatment of fistulasfistulas in Crohn's disease patientscomplex perianal fistulas and complex perianal fistulas in Crohn's disease patients; live cellular tissue implants in the nature of implants comprising living tissue or engineered live cellular tissue in the nature of implants comprising living tissue for medical purposes for the treatment of fistulasfistulas in Crohn's disease patientscomplex perianal fistulas and complex perianal fistulas in Crohn's disease patients
Publications
History of USPTO decisions and trademark events.
18 publications found
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
07/09/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/11/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
04/11/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/24/2023
PUBO
PUBLISHED FOR OPPOSITION
01/24/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/04/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/17/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/29/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/29/2022
ALIE
ASSIGNED TO LIE
11/28/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/07/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/20/2022
GNRT
NON-FINAL ACTION E-MAILED
09/20/2022
CNRT
NON-FINAL ACTION WRITTEN
09/20/2022
DOCK
ASSIGNED TO EXAMINER
09/13/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/07/2021
NWAP
NEW APPLICATION ENTERED
12/07/2021
Continuous trademark protection
Get notified about every new filing that threatens FISGENIQ or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.